Nuclear translocation of type I transforming growth factor β receptor confers a novel function in rna processing

Molecular and Cellular Biology

Volumn 32, Issue 12, 2012, Pages 2183-2195

  Chandra, Manasa ^a   Zang, Shengbing ^a,g   Li, Haiqing ^b   Zimmerman, Lisa J ^d,e   Champer, Jackson ^a   Tsuyada, Akihiro ^a   Chow, Amy ^a   Zhou, Weiying ^a   Yu, Yang ^f,g   Gao, Harry ^c   Ren, Xiubao ^f   Lin, Ren Jang ^a   Wang, Shizhen Emily ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Department of Bioinformatics Core Facility ^*  (United States)

^c DNA Sequencing/Solexa Core Facility   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f TIANJIN MEDICAL UNIVERSITY   (China)

^g FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; RNA; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ARTICLE; CELL MIGRATION; CELL NUCLEUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RNA SEQUENCE;

ALTERNATIVE SPLICING; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; FEMALE; HUMANS; KARYOPHERINS; PROTEIN TRANSPORT; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TRANSCRIPTION, GENETIC;

EID: 84864007262     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00320-12     Document Type: Article

References (51)

1. Albitar L, et al. 2010. EGFR isoforms and gene regulation in human endometrial cancer cells. Mol. Cancer 9:166.
2. Bailey TL, Williams N, Misleh C, Li WW. 2006. MEME: discovering and analyzing DNA and protein sequence motifs. Nucleic Acids Res. 34: W369-W373.
3. Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL. 2002. p38 mitogenactivated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J. Cell Sci. 115:3193-3206.
4. Baron AT, Wilken JA, Haggstrom DE, Goodrich ST, Maihle NJ. 2009. Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer. IDrugs 12:302-308.
5. Burd CG, Dreyfuss G. 1994. RNA binding specificity of hnRNP A1: significance of hnRNP A1 high-affinity binding sites in pre-mRNA splicing. EMBO J. 13:1197-1204.
6. Carpenter G. 2003. Nuclear localization and possible functions of receptor tyrosine kinases. Curr. Opin. Cell Biol. 15:143-148.
7. Chow A, Arteaga CL, Wang SE. 2011. When tumor suppressor TGFbeta meets the HER2 (ERBB2) oncogene. J. Mammary Gland Biol. Neoplasia 16:81-88.
8. Davis BN, Hilyard AC, Lagna G, Hata A. 2008. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 454:56-61.
9. Davis BN, Hilyard AC, Nguyen PH, Lagna G, Hata A. 2010. Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. Mol. Cell 39:373-384.
10. Dery KJ, et al. 2011. Mechanistic control of carcinoembryonic antigenrelated cell adhesion molecule-1 (CEACAM1) splice isoforms by the heterogeneous nuclear ribonuclear proteins hnRNP L, hnRNP A1, and hnRNP M. J. Biol. Chem. 286:16039-16051.
11. Derynck R, Akhurst RJ, Balmain A. 2001. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 29:117-129.
12. Derynck R, Zhang YE. 2003. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425:577-584.
13. Dumont N, Arteaga CL. 2003. Targeting the TGF beta signaling network in human neoplasia. Cancer Cell 3:531-536.
14. Ewan KB, et al. 2002. Latent transforming growth factor-beta activation in mammary gland: regulation by ovarian hormones affects ductal and alveolar proliferation. Am. J. Pathol. 160:2081-2093.
15. Farin K, Di Segni A, Mor A, Pinkas-Kramarski R. 2009. Structurefunction analysis of nucleolin and ErbB receptors interactions. PLoS One 4:e6128. doi:10.1371/journal.pone.0006128.
16. Feng XH, Derynck R. 1997. A kinase subdomain of transforming growth factor-beta (TGF-beta) type I receptor determines the TGF-beta intracellular signaling specificity. EMBO J. 16:3912-3923.
17. Feng XH, Derynck R. 2005. Specificity and versatility in tgf-beta signaling through Smads. Annu. Rev. Cell Dev. Biol. 21:659-693.
18. Giri DK, et al. 2005. Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. Mol. Cell. Biol. 25:11005-11018.
19. Ham AJL. 2004. Proteolytic digestion protocols, p 10-17. In Caprioli RM, Gross ML (ed), The encyclopedia of mass spectrometry, vol 2. Biological applications, part A. Elsevier, Oxford, United Kingdom.
20. Han SP, Tang YH, Smith R. 2010. Functional diversity of the hnRNPs: past, present and perspectives. Biochem. J. 430:379-392.
21. Heinz S, et al. 2010. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38:576-589.
22. Hercus C. 2009. Novocraft short read alignment package. http://ryanmlayer.files.wordpress.com/2009/10/novocraftv2-05.pdf.
23. Itoh S, et al. 2003. Elucidation of Smad requirement in transforming growth factor-beta type I receptor-induced responses. J. Biol. Chem. 278: 3751-3761.
24. Liu IM, et al. 2009. TGFbeta-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFbeta switch. EMBO J. 28:88-98.
25. Ly TK, et al. 2010. Activation of the Ran GTPase is subject to growth factor regulation and can give rise to cellular transformation. J. Biol. Chem. 285:5815-5826.
26. Ma ZQ, et al. 2009. IDPicker 2.0: improved protein assembly with high discrimination peptide identification filtering. J. Proteome Res. 8:3872-3881.
27. Martinez-Contreras R, et al. 2006. Intronic binding sites for hnRNP A/B and hnRNP F/H proteins stimulate pre-mRNA splicing. PLoS Biol. 4:e21. doi:10.1371/journal.pbio.0040021.
28. Massagué J, Blain SW, Lo RS. 2000. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103:295-309.
29. Massagué J, Gomis RR. 2006. The logic of TGFbeta signaling. FEBS Lett. 580:2811-2820.
30. Mu Y, et al. 2011. TRAF6 ubiquitinates TGFbeta type I receptor to promote its cleavage and nuclear translocation in cancer. Nat. Commun. 2:330.
31. Müller V, et al. 2006. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer. Anticancer Res. 26:1479-1487.
32. Muraoka-Cook RS, et al. 2006. Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene 25:3408-3423.
33. Muraoka RS, et al. 2003. Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol. Cell. Biol. 23:8691-8703.
34. Okunola HL, Krainer AR. 2009. Cooperative-binding and splicingrepressive properties of hnRNP A1. Mol. Cell. Biol. 29:5620-5631.
35. Persson U, et al. 1998. The L45 loop in type I receptors for TGF-beta family members is a critical determinant in specifying Smad isoform activation. FEBS Lett. 434:83-87.
36. Reiter JL, Maihle NJ. 1996. A 1.8 kb alternative transcript from the human epidermal growth factor receptor gene encodes a truncated form of the receptor. Nucleic Acids Res. 24:4050-4056.
37. Seton-Rogers SE, et al. 2004. Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 101:1257-1262.
38. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. 2003. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc. Natl. Acad. Sci. U. S. A. 100:8430-8435.
39. Stewart M. 2007. Molecular mechanism of the nuclear protein import cycle. Nat. Rev. Mol. Cell Biol. 8:195-208.
40. Tabb DL, Fernando CG, Chambers MC. 2007. MyriMatch: highly accurate tandem mass spectral peptide identification by multivariate hypergeometric analysis. J. Proteome Res. 6:654-661.
41. Ueda Y, et al. 2004. Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks TGF-induced cell motility. J. Biol. Chem. 279: 24505-24513.
42. Venables JP, et al. 2009. Cancer-associated regulation of alternative splicing. Nat. Struct. Mol. Biol. 16:670-676.
43. Wang SC, et al. 2004. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 6:251-261.
44. Wang SE, et al. 2006. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10:25-38.
45. Wang SE, et al. 2007. Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells. J. Biol. Chem. 282:5661-5669.
46. Wang SE, Shin I, Wu FY, Friedman DB, Arteaga CL. 2006. HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta. Cancer Res. 66:9591-9600.
47. Wang SE, et al. 2004. Early activation of the Kaposi's sarcoma-associated herpesvirus RTA, RAP, andMTApromoters by the tetradecanoyl phorbol acetate-induced AP1 pathway. J. Virol. 78:4248-4267.
48. Wang SE, Wu FY, Shin I, Qu S, Arteaga CL. 2005. Transforming growth factor beta (TGF-beta)-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-beta function. Mol. Cell. Biol. 25:4703-4715.
49. Wang SE, et al. 2008. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol. Cell. Biol. 28:5605-5620.
50. Yu Y, et al. 2010. Context-dependent bidirectional regulation of the MutS homolog 2 by transforming growth factor beta contributes to chemoresistance in breast cancer cells. Mol. Cancer Res. 8:1633-1642.
51. Zhang B, Chambers MC, Tabb DL. 2007. Proteomic parsimony through bipartite graph analysis improves accuracy and transparency. J. Proteome Res. 6:3549-3557.